Clinical Trial

A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination

Name: A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination — clinical trial record (NCT07330440)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Enrolling by Invitation Phase 1

View on ClinicalTrials.gov →

Summary

A Preliminary Evaluation of the Safety and Immunogenicity Post-Vaccination with Different Doses of an mRNA Vaccine against Herpes Simplex Virus Type 2 (HSV-2) in Populations with Different Serostatus

Trial Details

NCT Number	NCT07330440
Lead Sponsor	Changchun BCHT Biotechnology Co.
Conditions	Genital Herpes
Enrollment	144 participants
Start Date	2025-10-13
Primary Completion	2027-03-04 (estimated)
Study Completion	2027-06 (estimated)
Updated on ClinicalTrials.gov	2026-01-09